Literature DB >> 1906940

Antigenicity and accessory cell function of human articular chondrocytes.

S Alsalameh1, B Jahn, A Krause, J R Kalden, G R Burmester.   

Abstract

It is postulated that chondrocytes may be actively involved in the pathogenesis of inflammatory joint diseases, presumably by providing tissue specific antigens that may initiate or sustain autoimmune reactions. To investigate whether chondrocytes may also function as accessory cells in ongoing immune processes, mixed leukocyte-chondrocyte cultures and antigen presentation assays were studied. Freshly isolated and short term cultured HLA class II antigen (Ia) negative as well as gamma-interferon treated Ia positive chondrocytes were weakly or not stimulatory to allogeneic or autologous resting lymphocytes derived from either normal donors or patients with rheumatoid arthritis. In an antigen presenting system using tetanus toxoid, the majority of chondrocyte preparations tested induced an antigen driven response in HLA matched allogeneic or autologous resting T cells which, however, was much less when compared to blood monocytes. In contrast, using activated T cells derived from tetanus toxoid specific T cell lines, an efficient antigen presenting capacity could be demonstrated in both Ia positive and initially Ia negative chondrocytes. Interestingly, the latter population had acquired Ia antigens upon incubation with the T cell line.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906940

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Cellular responses to human chondrocytes: absence of allogeneic responses in the presence of HLA-DR and ICAM-1.

Authors:  P Jobanputra; V Corrigall; G Kingsley; G Panayi
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Stimulation of rheumatoid synovial and blood T cells and lines by synovial fluid and interleukin-2: characterization of clones and recognition of a co-stimulatory effect.

Authors:  N Hain; S Alsalameh; W M Bertling; J R Kalden; G R Burmester
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  Enhanced production of MMP-1, MMP-3, MMP-13, and RANTES by interaction of chondrocytes with autologous T cells.

Authors:  Hiroshi Nakamura; Michiaki Tanaka; Kayo Masuko-Hongo; Kazuo Yudoh; Tomohiro Kato; Moroe Beppu; Kusuki Nishioka
Journal:  Rheumatol Int       Date:  2006-02-09       Impact factor: 2.631

4.  Expression of ICAM-1 on intact cartilage and isolated chondrocytes.

Authors:  J Bujia; U Behrends; N Rotter; P Pitzke; E Wilmes; C Hammer
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-02       Impact factor: 2.416

Review 5.  Antigen-presenting cell engineering. The molecular toolbox.

Authors:  M L Tykocinski; D R Kaplan; M E Medof
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

6.  Cytotoxic T lymphocytes recognize and lyse chondrocytes under inflammatory, but not non-inflammatory conditions.

Authors:  E Suzanne Cohen; Helen C Bodmer
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

7.  Chondrocyte-peripheral blood mononuclear cell interactions: the role of ICAM-1.

Authors:  A Horner; M E Davies; B Franz
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

8.  Immunoglobulin deposits in synovial membrane and cartilage and phenotype analysis of chondrocyte antigens in sheep infected with the visna retrovirus.

Authors:  G D Harkiss; C Green; A Anderson; N J Watt
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

9.  Detection of cytokine activated chondrocytes in arthritic joints from pigs infected with Erysipelothrix rhusiopathiae.

Authors:  M E Davies; A Horner; B Franz; H J Schuberth
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

10.  Genome-wide gene expression analysis suggests an important role of suppressed immunity in pathogenesis of Kashin-Beck disease.

Authors:  Shuang Wang; Xiong Guo; Xiao-ming Wu; Mikko J Lammi
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.